Compatibility of PID testing with clinical specimens was then evaluated in a series of 108 well characterized breast cancer specimens, comparing HER2 immunofluorescence with PID to HER2 IHC with 3, 3′-diaminobenzidine (DAB)detection and HER2 ISH gene detection. Here, ERBB2 is linked to breast carcinoma.